Logo image of PACS

PACS GROUP INC (PACS) Stock Fundamental Analysis

NYSE:PACS - New York Stock Exchange, Inc. - US69380Q1076 - Common Stock - Currency: USD

10.99  +0.37 (+3.48%)

After market: 10.77 -0.22 (-2%)

Fundamental Rating

3

Taking everything into account, PACS scores 3 out of 10 in our fundamental rating. PACS was compared to 103 industry peers in the Health Care Providers & Services industry. PACS has a bad profitability rating. Also its financial health evaluation is rather negative. PACS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

PACS had positive earnings in the past year.
PACS Yearly Net Income VS EBIT VS OCF VS FCFPACS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

The Return On Assets of PACS (2.90%) is better than 64.08% of its industry peers.
With an excellent Return On Equity value of 19.73%, PACS belongs to the best of the industry, outperforming 87.38% of the companies in the same industry.
PACS has a Return On Invested Capital (4.38%) which is in line with its industry peers.
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROIC 4.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PACS Yearly ROA, ROE, ROICPACS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 50 100 150 200

1.3 Margins

PACS has a Profit Margin of 3.63%. This is in the better half of the industry: PACS outperforms 68.93% of its industry peers.
Looking at the Operating Margin, with a value of 6.68%, PACS is in the better half of the industry, outperforming 69.90% of the companies in the same industry.
Looking at the Gross Margin, with a value of 21.33%, PACS is in line with its industry, outperforming 45.63% of the companies in the same industry.
Industry RankSector Rank
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PACS Yearly Profit, Operating, Gross MarginsPACS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PACS is destroying value.
PACS has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for PACS is higher compared to a year ago.
PACS Yearly Shares OutstandingPACS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 50M 100M
PACS Yearly Total Debt VS Total AssetsPACS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 1B 2B 3B

2.2 Solvency

PACS has an Altman-Z score of 1.41. This is a bad value and indicates that PACS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.41, PACS is doing worse than 64.08% of the companies in the same industry.
A Debt/Equity ratio of 0.90 indicates that PACS is somewhat dependend on debt financing.
PACS has a Debt to Equity ratio of 0.90. This is in the lower half of the industry: PACS underperforms 62.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 1.41
ROIC/WACC0.5
WACC8.72%
PACS Yearly LT Debt VS Equity VS FCFPACS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.71 indicates that PACS should not have too much problems paying its short term obligations.
PACS's Current ratio of 1.71 is fine compared to the rest of the industry. PACS outperforms 61.16% of its industry peers.
A Quick Ratio of 1.71 indicates that PACS should not have too much problems paying its short term obligations.
The Quick ratio of PACS (1.71) is better than 65.05% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
PACS Yearly Current Assets VS Current LiabilitesPACS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for PACS have decreased strongly by -25.00% in the last year.
The Revenue has grown by 28.47% in the past year. This is a very strong growth!
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%

3.2 Future

PACS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.87% yearly.
Based on estimates for the next years, PACS will show a quite strong growth in Revenue. The Revenue will grow by 18.92% on average per year.
EPS Next Y92.3%
EPS Next 2Y39.97%
EPS Next 3Y33.87%
EPS Next 5YN/A
Revenue Next Year28.62%
Revenue Next 2Y22.64%
Revenue Next 3Y18.92%
Revenue Next 5YN/A

3.3 Evolution

PACS Yearly Revenue VS EstimatesPACS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B 5B
PACS Yearly EPS VS EstimatesPACS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0.5 1 1.5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.46 indicates a correct valuation of PACS.
Based on the Price/Earnings ratio, PACS is valued a bit cheaper than the industry average as 78.64% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.24, PACS is valued a bit cheaper.
The Price/Forward Earnings ratio is 7.34, which indicates a rather cheap valuation of PACS.
91.26% of the companies in the same industry are more expensive than PACS, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of PACS to the average of the S&P500 Index (36.42), we can say PACS is valued rather cheaply.
Industry RankSector Rank
PE 14.46
Fwd PE 7.34
PACS Price Earnings VS Forward Price EarningsPACS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PACS is valued a bit cheaper than the industry average as 67.96% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.03
PACS Per share dataPACS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PACS's earnings are expected to grow with 33.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y39.97%
EPS Next 3Y33.87%

More info and screens

0

5. Dividend

5.1 Amount

PACS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACS GROUP INC

NYSE:PACS (8/4/2025, 8:04:01 PM)

After market: 10.77 -0.22 (-2%)

10.99

+0.37 (+3.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners29.85%
Inst Owner Change0.12%
Ins Owners71.98%
Ins Owner Change-0.49%
Market Cap1.71B
Analysts82
Price Target35.09 (219.29%)
Short Float %5.68%
Short Ratio4.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.28%
Min EPS beat(2)24.18%
Max EPS beat(2)56.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.83%
Min Revenue beat(2)2.62%
Max Revenue beat(2)5.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.41%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.18%
Revenue NY rev (1m)-0.87%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE 14.46
Fwd PE 7.34
P/S 0.55
P/FCF N/A
P/OCF N/A
P/B 2.98
P/tB 3.36
EV/EBITDA 9.03
EPS(TTM)0.76
EY6.92%
EPS(NY)1.5
Fwd EY13.62%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS20.05
BVpS3.69
TBVpS3.27
PEG (NY)0.16
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROCE 6.06%
ROIC 4.38%
ROICexc 4.47%
ROICexgc 4.56%
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA 2.21
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z 1.41
F-ScoreN/A
WACC8.72%
ROIC/WACC0.5
Cap/Depr(3y)671.95%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
EPS Next Y92.3%
EPS Next 2Y39.97%
EPS Next 3Y33.87%
EPS Next 5YN/A
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%
Revenue Next Year28.62%
Revenue Next 2Y22.64%
Revenue Next 3Y18.92%
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.44%
EBIT Next 3Y37.58%
EBIT Next 5YN/A
FCF growth 1Y-74.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.22%
OCF growth 3YN/A
OCF growth 5YN/A